Asset Details
Do you wish to reserve the book?
Single Center, Open‐Label, Randomized Crossover Trial on Drug–Drug Interactions of Levothyroxine/Magnesium‐Citrate and Levothyroxine/Magnesium‐Aspartate in Healthy Subjects—The ThyroMag Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Single Center, Open‐Label, Randomized Crossover Trial on Drug–Drug Interactions of Levothyroxine/Magnesium‐Citrate and Levothyroxine/Magnesium‐Aspartate in Healthy Subjects—The ThyroMag Trial
Do you wish to request the book?
Single Center, Open‐Label, Randomized Crossover Trial on Drug–Drug Interactions of Levothyroxine/Magnesium‐Citrate and Levothyroxine/Magnesium‐Aspartate in Healthy Subjects—The ThyroMag Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Single Center, Open‐Label, Randomized Crossover Trial on Drug–Drug Interactions of Levothyroxine/Magnesium‐Citrate and Levothyroxine/Magnesium‐Aspartate in Healthy Subjects—The ThyroMag Trial
2025
Overview
Divalent cations such as calcium and ferrous sulfate interfere with the absorption of levothyroxine due to complexing. To our knowledge, the effects of magnesium on levothyroxine absorption have never been studied. The open‐label cross‐over pharmacokinetic study was conducted in 15 healthy, euthyroid adults. 1 mg of levothyroxine was administered in tablet form alone or co‐administered with either magnesium aspartate or magnesium citrate. Participants received all three treatments, separated by a washout period, but were randomly allocated 1:1:1 to one of three treatment sequences. We measured thyroxine (T4) over a 6‐h period after ingestion. The primary endpoint was the area under the curve (AUC) of thyroxine; secondary endpoints were Cmax and Tmax. Coadministration of magnesium aspartate significantly reduced thyroxine AUC by 12% (geometric mean ratio, GMR = 0.88, 95% CI 0.81–0.95, p = 0.002) and coadministration of magnesium citrate reduced thyroxine AUC non‐significantly by 7% compared with levothyroxine alone (GMR = 0.93, 95% CI 0.86–1.01, p = 0.076). Cmax was significantly reduced by 7% and Tmax was significantly increased by 17% when magnesium aspartate was co‐administered. The changes in Cmax and Tmax were smaller when magnesium citrate was co‐administered. In conclusion, magnesium reduces the absorption of levothyroxine. However, we found smaller effects compared to those already described for other divalent cations, possibly due to the liquid formulation. Hypothyroid patients should nonetheless take levothyroxine separated from magnesium‐containing formulations, especially if TSH levels are desired to be within a narrow range. If taken together, magnesium citrate may be a better option than magnesium aspartate.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Aluminum
/ Aspartic Acid - administration & dosage
/ Aspartic Acid - pharmacokinetics
/ Citric Acid - administration & dosage
/ Citric Acid - pharmacokinetics
/ Female
/ Humans
/ Magnesium Compounds - administration & dosage
/ Magnesium Compounds - pharmacokinetics
/ Male
/ Thyroxine - administration & dosage
